Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study finds miRNAs inhibits prostate cancer metastasis

A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein commonly found on prostate cancer stem cells. A research team led by scientists at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine.

18 Jan 2011

14 foods that deliver research-documented benefits to health

With the start of a new year, many of us resolve to better our habits by trying to incorporate more nutritious foods into our diets. An article in the January issue of Food Technology magazine lists 14 foods that deliver research-documented benefits to health.

14 Jan 2011

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

Journal of the National Cancer Institute: Projections Of The Cost Of Cancer Care In The United States: 2010-2020 - "By combining cancer prevalence with average annual costs of cancer care by phase of care and tumor site for 13 cancers in men and 16 cancers in women" and "all cancer sites combined," the authors project there will be just over 18 million cancer survivors in 2020 compared to 13.8 million survivors in 2010.

14 Jan 2011

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

Researchers at the Duke Cancer Institute who have been studying prostate cancer cells for decades now think they know why PSA levels reflect cancer progression.

14 Jan 2011

Study highlights role of SIRT1 protein as tumor suppressor in prostate cancer

Researchers from the Kimmel Cancer Center at Jefferson and two other institutions have discovered new evidence that suggests the "longevity" protein SIRT1, known for its life-spanning effects in different species, can inhibit the development of a known precursor to prostate cancer, prostatic intraepithelial neoplasia.

14 Jan 2011

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.

13 Jan 2011

Epigenomics concludes feasibility phase in development of improved product concept for Epi proColon

Epigenomics AG, the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an improved product concept for Epi proColon, the Company's DNA methylation-based blood test for assistance in the detection of individuals with colorectal cancer.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Beth Israel Deaconess Medical Center cancer geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient of the 2011 Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research.

13 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.

12 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Behavioral therapies such as pelvic-floor-muscle training and bladder-control strategies can reduce incontinence episodes by more than 50 percent in men following prostate-cancer surgery, according to new research from the Center for Aging at the University of Alabama at Birmingham and the Birmingham/Atlanta Veterans Affairs Geriatric Research, Education and Clinical Center.

12 Jan 2011

Acne bacterium may also cause infections all over the body

A bacterium which causes acne and is commonly found on the skin, is now known to cause infections all over the body. Propionibacterium acnes (P. acnes)5 has been associated with infections of artificial joints and heart valves (endocarditis), as well as eye infections and chest infections - which are common at this time of year.

12 Jan 2011

BPH, hair loss prevention drugs may produce adverse side effects in men

Researchers from Boston University School of Medicine, in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors, while improving urinary symptoms in patients with benign prostatic hyperplasia and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction, ejaculatory dysfunction and potential depression.

12 Jan 2011

Study to identify early warning biomarkers for presence of breast and prostate cancers

Using biological samples taken from patients and state-of-the-art biochemical techniques, a Florida State University researcher is working to identify a variety of "biomarkers" that might provide earlier warnings of the presence of breast and prostate cancers.

11 Jan 2011

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Virginia Commonwealth University Massey Cancer Center has introduced a safer and more effective form of radiation therapy to treat cancer. The Center now offers volumetric modulated arc therapy (VMAT) delivery using the Philips Pinnacle3 SmartArc software to provide radiation treatment for multiple tumor sites, including prostate, head and neck, brain, breast and lung. VCU Massey is the first cancer center in the Richmond area to offer this cutting-edge radiation technique.

10 Jan 2011

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Study finds miRNAs inhibits prostate cancer metastasis

14 foods that deliver research-documented benefits to health

Research roundup: Racial disparities in cancer and other care, nursing home closures, extending drugmakers' exclusivity

Scientists demonstrate mechanism that explains why PSA levels promote prostate cancer

Study highlights role of SIRT1 protein as tumor suppressor in prostate cancer

Therapeutic workshops selected for presentation at the Thirteenth Annual BIO CEO & Investor Conference

Epigenomics concludes feasibility phase in development of improved product concept for Epi proColon

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Negative aspects of prostate cancer screening acceptable

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Acne bacterium may also cause infections all over the body

BPH, hair loss prevention drugs may produce adverse side effects in men

Study to identify early warning biomarkers for presence of breast and prostate cancers

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in